Skip to main content

Miltefosine for leishmaniasis: molecular basis of mechanisms of action, resistance and combination therapy (MILTLEISH)

Objective

Miltefosine, an alkylphospholipid first developed as an anticancer drug, has been shown to have activity against Leis mania species and is a new oral drug for the treatment of visceral leishmaniasis. There is little understanding of the mechanism(s) of action or resistance of this drug in Leis mania. This project will characterise drug targets and resistance mechanisms in L.donovani through molecular/biochemical techniques and chemical structure-activity studies. Results will be used to design strategies to avoid or overcome drug resistance, including drug combinations. Target characterisation will be used as the basis for the identification of further antiprotozoal drugs.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Address
Keppel Street
London
United Kingdom

Participants (4)

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Spain
Address
11,Calle Ventanilla 11
18001 Granada
EUROPEPTIDES (GEIE)
France
Address
Avenue Du Marais 9
95100 Argenteuil
FREIE UNIVERSITAET BERLIN
Germany
Address
Kelchstrasse 31
12169 Berlin
UNIVERSITE DE PARIS-SUD XI
France
Address
Rue Jean-baptiste Clément 3
92290 Chatenay Malabry